Pierre Vandepapeliere MD, PhD

Pierre Vandepapelière, M.D.,PhD is CEO and CMO of Imcyse since February 2015. He has transformed an academic research group into a rapidly growing Biotech company. Imcyse is a biotech company developing a technology platform offering multiples opportunities such as active specific immunotherapeutics (Imotopes) to treat and to prevent auto immune diseases or allergic diseases or to down regulation of immune response against immunogenic drugs. Before joining Imcyse he was head of early clinical research at GlaxoSmithKline Biologicals. He has extended experience in development of vaccines worldwide, specifically therapeutic vaccines for chronic infectious diseases, and in the evaluation and use of adjuvants in vaccines. Pierre also spent 7 years as head of development at Neovacs, Paris, and as consultant he implemented phase IIb programs in other Biotech companies. He graduated in Medicine at the Catholic University of Louvain, in Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium and has a PhD from the University of Gent.